[{"orgOrder":0,"company":"Kindeva Drug Delivery","sponsor":"U.S. Department of Health and Human Services","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"Atropine","moa":"||mAChR-M1\/M2\/M3","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Kindeva Drug Delivery","amount2":0.13,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0.13,"dosageForm":"Injection","sponsorNew":"Kindeva Drug Delivery \/ U.S. Department of Health and Human Services","highestDevelopmentStatusID":"15","companyTruncated":"Kindeva Drug Delivery \/ U.S. Department of Health and Human Services"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          RNA Therapeutics
                          Not Confirmed
                          RNA Therapeutics
                          Not Confirmed

                          Details : The funding aims to advance the the manufacturing of DuoDote (atropine and pralidoxime chloride). It is indicated for the treatment of poisoning by organophosphorus nerve agents.

                          Product Name : Duodote

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 16, 2025

                          Lead Product(s) : Atropine,Pralidoxime Chloride

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Approved FDF

                          Sponsor : U.S. Department of Health and Human Services

                          Deal Size : $129.0 million

                          Deal Type : Funding

                          blank